This review highlights the need for enhancements in doxorubicin chemistry, delivery, and toxicity management to prolong its clinical utility against cancer.
Overall the future for the continued use of doxorubicin clinically against cancer looks set to be prolonged, provided certain enhancements as listed above are made to its chemistry, delivery and toxicity. Increased efficacy depends on these three aims being met satisfactorily as discussed in turn in this review.
Tacar et al. (Fri,) studied this question.